Skip to content

Holo CTO Proctoring Study

Holo CTO Proctoring Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05377866
Enrollment
10
Registered
2022-05-17
Start date
2021-11-04
Completion date
2023-01-31
Last updated
2023-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention

Brief summary

Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures

Detailed description

Proctoring in medicine is related to better outcomes. Specifically, in CTO PCI systematic proctoring has demonstrated improved success rates, and an increased ability to treat lesions that are more complex. Most likely, proctoring together with operator volume is one of the foundations to the introduction and execution of CTO procedures. Proctoring traditionally involves an expert operator (proctor), visiting the institution, performing the procedure together with the local operator. This involves increased cost, and current travel restrictions makes traditional one-on-one proctoring challenging. This study aims to evaluate the Microsoft HoloLens as a potential platform in proctoring and effective real time communication between PCI operators located at different geographical locations. The proctor and the local operator interact using a head mounted mixed reality (MR) display, enabling the proctor to see the same image as the operator, from any distanced location.

Interventions

OTHERRemote proctoring using HoloLens

Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.

Sponsors

Oslo University Hospital
CollaboratorOTHER
HoloCare AS
CollaboratorINDUSTRY
Sorlandet Hospital HF
Lead SponsorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Clinical inclusion criteria: * Stable angina pectoris, or dyspnoea as an angina equivalent * Age ≥18 yrs. * Able to provide written informed consent Angiographic inclusion criteria: * One or more completely occluded coronary arteries with Thrombolysis In Myocardial Infarction (TIMI) flow 0. An estimated occlusion duration of at least 3 months * Absence of Q-wave in ECG leads corresponding to the occluded vessel, or documented viability of the main territory by MRI or echocardiography Procedural inclusion criteria: * Clinical indication for CTO PCI regardless of operative technique

Exclusion criteria

* STEMI within 72 hours * Cardiogenic shock * Active bleeding or coagulopathy * Life expectancy \< 2 years * Relevant allergies (aspirin, clopidrogrel, ticagrelol, contrast compounds) * Severe peripheral artery disease * Clinical unstable angina

Design outcomes

Primary

MeasureTime frameDescription
Standard Usability Score on a Likert ScaleProcedure duration( aprox 120 min)The operators completing the intervention will rate the usability of the system on a Likert scale: 1. The HoloLens was useful in this procedure 2. The HoloLens was not distracting 3. The HoloLens was comfortable to wear 4. The HoloLens camera image has sufficient quality for clinical use (not considering the fluoroscopy screen) 5. Compared to an alternative system with fluoroscopy image plus handsfree voice (telephone), the HoloLens gives additional value during the procedure 6. The current solution with Remote Assist plus parallel fluoroscopy streaming is mature enough for routine use 7. The current solution is stable 8. The current solution is easy to set up prior to the procedure 9. I would like to continue to use the HoloLens in CTO procedures routinely when remote proctoring is needed Agree to Disagree Likert Scale * Strongly Disagree * Disagree * Neither agree nor disagree * Agree * Strongly Agree

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026